PBAC's latest decision on Nab-paclitaxel: Not recommended (2015). Considered for Treatment of HER2-positive metastatic breast cancer in combination with trastuzumab.
PBAC outcome
Not recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Patients with HER2-positive metastatic breast cancer receiving trastuzumab (later lines of therapy).
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
Single-arm
Primary endpoint
ORR
Pivotal trial size
72 patients
Key trials
Mirtsching et al 2011, Colin et al 2010
Comparator
solvent-based paclitaxel and docetaxel
Economic model
Cost-minimisation
Budget impact
$1M
ICER note
This was a minor submission (price reduction only); no ICER was modelled. The submission was cost-minimisation in nature, not an economic evaluation with ICER.
Why PBAC said no
Reasons cited in the latest PSD: no clear evidence for improved efficacy of nab-paclitaxel over solvent-based paclitaxel or docetaxel; no basis to justify the cost premium over comparators; cost of nab-paclitaxel more than 30 times that of solvent-based paclitaxel